

Used in Lieu of PTO/SB/08A/B
(Based on PTO 01-08 version)

Substitute for form 1449/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/623,039-Conf. #1401	
			Filing Date	July 18, 2003	
			First Named Inventor	Subhashis BANERJEE	
			Art Unit	1643	
			Examiner Name	D. J. Blanchard	
Sheet	1	of	2	Attorney Docket Number	117813-18801

U.S. PATENT DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	Document Number Number-Kind Code ² (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	US 2009-0155205 A1	06-18-2009	Salfeld et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	⁶
	B1	WO-02/12502-A3	02-14-2002	Giles-Komar et al.		

Examiner Signature	/David Blanchard/	Date Considered	09/14/2009
---------------------------	-------------------	------------------------	------------

¹EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ²CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.96(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ³Applicant's unique citation designation number (optional). ⁴See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁵Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁶For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁷Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁸Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		²
	C1	Aboulafia, D., "Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis," Mayo Clinic Proceedings, 75(10): 1093-1098 (2002)		
	C2	Antoni, C., et al., "Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation," Arthritis & Rheumatism, Vol. 47(5): 506-512 (2002)		
	C3	Colman, PM, "Effects of amino acid sequence changes on antibody-antigen interactions," Res. Immunol, Vol. 145(1):33-36 (1994)		
	C4	Elkayam, O., et al., "From wheels to feet: a dramatic response of severe chronic psoriatic arthritis to etanercept," Ann. Rheumatic Diseases, Vol. 59: 839 (2000)		
	C5	Iyer, S., et al., "Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy," British Journal of Dermatology, Vol. 146: 118-121 (2002)		

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).	
Dated: August 6, 2009	Electronic Signature for Cristin Howley Cowles, Ph.D.: /Cristin Howley Cowles, Ph.D./

ME1 8882171v.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.B./

Used in Lieu of PTO/SB/08A/B
(Based on PTO 01-08 version)

Substitute for form 1449/PTO			Complete if known Application Number 10/623,039-Conf. #1401 Filing Date July 18, 2003 First Named Inventor Subhashis BANERJEE Art Unit 1643 Examiner Name D. J. Blanchard Attorney Docket Number 117813-18801	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				
Sheet	2	of	2	

C6	Kurschat, P., et al., "Treatment of psoriatic arthritis with etanercept," J Am Acad Dermatology, Vol. 44(6): 1052 (2001)	
C7	Lipsy, R., "Etanercept and its implications for managed care," Am J of Managed Care, Vol. 8(6), S194-S200 (2002)	
C8	Mease, P.J., "Cytokine blockers in psoriatic arthritis," Ann Rheum Dis, Vol. 60:iii37-iii40 (2001)	
C9	Mease, P.J., et al., "Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial," Lancet, Vol. 356(9227): 385-390 (2000)	
C10	Mease, P.J., "Etanercept: A new era in the treatment of psoriatic arthritis," Am J of Managed Care, Vol. 8(6): S181-S193 (2002)	
C11	Yazici, Y., et al., "A preliminary study of etanercept in the treatment of severe, resistant psoriatic arthritis," Clinical and Experimental Rheumatology, Vol. 18:732-734 (2000)	
C12	Yazici, Y., et al., "Etanercept in the treatment of severe, resistant psoriatic arthritis: Continued efficacy and changing patterns of use after two years," J Am Acad Dermatology, Vol. 44(6): 1052 (2001)	
C13	Prescribing Information for Humira (adalimumab) Injection, Solution for Subcutaneous use Initial U.S. Approval: 2002 (Updated March 2009)	
C14	Office Action cited during prosecution of US Patent Application No. 11/435,844, dated February 9, 2009 (Examiner: D.J. Blanchard)	

Examiner Signature	/David Blanchard/	Date Considered	09/14/2009
--------------------	-------------------	-----------------	------------

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609 Draw line through citation if not in conformance and not considered Include copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.B./